Renascience Inc.
Notification of Completion of Patient Dosing in the Phase III Trial of RS5614, a PAI-1 Inhibitor, in Combination with Tyrosine Kinase Inhibitors (TKIs) for Chronic Myeloid Leukemia
Dosing of 57 enrolled patients was completed in the Phase III trial of the RS5614 combination therapy. Data analysis and preparation of the clinical study report will follow. Direct impact on fiscal 2027 performance is currently unknown.
Key Figures
- 57 people: Number of enrolled patients / dosing completed
- 2026-09-29: Dosing completion date
- Impact on fiscal 2027 results: Unknown
AI要約
Completion of the Clinical Trial and Next Steps for Evaluation
Dosing for all 57 enrolled patients in the investigator-initiated Phase III trial of RS5614 combination therapy for chronic myeloid leukemia (CML) was completed on September 29, 2026. This investigational therapy, administered in combination with TKIs, aims to achieve deep molecular response (DMR). The results will be summarized in a clinical study report and undergo data analysis and evaluation. With support from AMED, the project will continue to evaluate a treatment strategy aiming for treatment-free remission (TFR) after maintaining DMR for more than two years.
Future Schedule and Impact
This trial is a confirmatory study intended to support regulatory approval; if efficacy is demonstrated, it could provide a new treatment option for CML patients. At this time, the direct impact on fiscal 2027 results is unknown, and future valuation and development progress may be reflected in corporate value depending on trial outcomes.
Renascience Inc.
Company overview · Stock price · Financial data · All IR
